News | June 05, 2021
Jubilant Pharmova posts Q4FY21 consolidated PAT of Rs. 213.90 Cr
The company is doubling its chemistry research capacity that should commission by Q2'FY22
The company is doubling its chemistry research capacity that should commission by Q2'FY22
Arformoterol Tartrate Inhalation Solution is for treatment of bronchoconstriction
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
For the year ended March 31, 2021, consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period
The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
This marks Glenmark's first synthetic decapeptide injectable approval
The company plans to enter the EU markets in FY22
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
NATCO Pharmaceuticals, Hyderabad; Alembic Pharmaceuticals, Vadodara; Gufic Biosciences Ltd., Gujarat; Emcure Pharmaceuticals, Pune; and Lyka, Gujarat are new manufacturers
Allecra Therapeutics would now either directly or through out license file for NDA of this molecule.
Subscribe To Our Newsletter & Stay Updated
